Citadel Advisors’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Citadel Advisors’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24,000	Closed	-$26K	–	14703
2022 Q1	$26K	Sell	24,000 -22,800	-49%	-$41.4K	﹤0.01%	13168
2021 Q4	$89K	Buy	46,800 +14,200	+44%	+$34K	﹤0.01%	12837
2021 Q3	$98K	Sell	32,600 -20,500	-39%	-$73K	﹤0.01%	12908
2021 Q2	$208K	Sell	53,100 -8,700	-14%	-$36.1K	﹤0.01%	12078
2021 Q1	$313K	Buy	+61,800	New	+$321K	﹤0.01%	10752
2020 Q3	–	Sell	-14,000	Closed	-$78K	–	10989
2020 Q2	$78K	Buy	+14,000	New	+$64.1K	﹤0.01%	9121

Citadel Advisors's AGTC Position: Q4 2022 in Review

Citadel Advisors sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 423,709 shares — an estimated $115K sold.

Citadel Advisors first reported a position in AGTC in Q1 2015 and held it in 15 quarters. The position peaked at $1.14M in Q1 2016. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.

Citadel Advisors reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 423,709 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $115K.
Citadel Advisors first reported a position in Applied Genetic Technologies Corporation in Q1 2015 and held it in 15 quarters.
Citadel Advisors's Applied Genetic Technologies Corporation position peaked at $1.14M in Q1 2016.
0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.